Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - ScienceDirect
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
PARP inhibitor in Ca Ovary | PPT
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count : results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) -
Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - Gynecologic Oncology
Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study | Future Oncology
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
PARP Inhibitors. - ppt download
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab - ScienceDirect
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy | ZEJULA (niraparib) for HCPs
Efficacy of niraparib in the PRIMA phase III trial | Download Scientific Diagram
Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - European Journal of
Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context | Future Oncology
Current Oncology | Free Full-Text | A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
PRIMA study design. CR complete response, PR partial response, PFS... | Download Scientific Diagram
Use of First-Line PARP Inhibitors in Ovarian Cancer | Published in healthbook TIMES Oncology Hematology
Niraparib Efficacy and Safety in Patients with BRCA-Mutated (BRCAm) Ovarian Cancer: Results from Three Phase 3 Niraparib Trials
Zejula (Niraparib) First PARP Inhibitor Approved for First-Line Maintenance Therapy in All Women with Advanced Ovarian Cancer, Regardless of Biomarker Status
Personalized Dosing of Niraparib in Ovarian Cancer - YouTube
